Earnings Feed
Start Free
Dyne Therapeutics, Inc.·4

Jun 22, 4:15 PM ET

Kersten Dirk 4

Research Summary

AI-generated summary

Updated

Dyne Therapeutics (DYN) Director Dirk Kersten Sells Shares

What Happened

  • Dirk Kersten, a director of Dyne Therapeutics (DYN), reported sales of a total of 84,355 shares via open-market transactions on June 17 and June 18, 2026. The sales generated approximately $1,695,689 in proceeds (37,454 shares at a $20.14 weighted average = $754,316; 46,901 shares at a $20.07 weighted average = $941,373).
  • These were sales (not purchases), which are typically routine disposition activity rather than a bullish signal.

Key Details

  • Transaction dates and prices:
    • 2026-06-17: 37,454 shares sold at a $20.14 weighted average (individual trades ranged $20.00–$20.43).
    • 2026-06-18: 46,901 shares sold at a $20.07 weighted average (individual trades ranged $20.00–$20.485).
  • Total proceeds: ~ $1.70 million.
  • Shares owned after transaction: Not specified in the provided filing details.
  • Notable footnotes:
    • Sales were made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. on November 11, 2025 (footnote F1).
    • The reported shares are held directly by ForDyne B.V., an entity jointly owned/managed by Forbion funds; Kersten is a partner of the management entities and is affiliated with ForDyne’s investment committee (footnotes F3–F4). Kersten disclaims direct beneficial ownership except for any pecuniary interest.
    • Weighted-average prices reported; the filer offered to provide per-trade price breakdowns on request (footnotes F2, F5).
  • Filing timeliness: Form filed on 2026-06-22 for trades on 6/17–6/18. Form 4s are generally due within two business days of a transaction, so this filing was later than that standard window.

Context

  • These sales were executed under a pre-established 10b5-1 plan by an entity (ForDyne) tied to institutional investment funds; this is institutional/plan-driven selling rather than a straightforward personal sale by an unaffiliated executive.
  • For retail investors: purchases tend to be more informative of insider conviction; routine sales under a trading plan are common and do not alone indicate a change in company outlook.